Angiogenesis Inhibition PDF Download
Are you looking for read ebook online? Search for your book and save it on your Kindle device, PC, phones or tablets. Download Angiogenesis Inhibition PDF full book. Access full book title Angiogenesis Inhibition by Rüdiger Liersch. Download full books in PDF and EPUB format.
Author: Rüdiger Liersch
Publisher: Springer Science & Business Media
ISBN: 3540782818
Category : Medical
Languages : en
Pages : 238
Get Book Here
Book Description
Angiogenesis is attracting increased scientific and clinical interest. The identification of novel mediators and targeting molecules has led to significant progress in our understanding of tumor angiogenesis and tumor vessel targeting. Important advances in cancer treatment have already emerged, and in the future, blood vessel targeting will play a significant role within individualized therapeutic strategies. This volume provides a general overview of the latest developments in angiogenesis inhibition in cancer. All aspects from the bench to the bedside are considered, with detailed attention both to basic research and to its translation into clinical practice. Individual chapters are devoted to the roles of angiopoietins, HIF-1a, chemokines, PDGF and VEGF, and vascular integrins. The latest results of clinical trials are presented, and various advanced targeting strategies are discussed. This book will be invaluable to all who wish to learn of the most recent advances in this exciting field.
Author: Rüdiger Liersch
Publisher: Springer Science & Business Media
ISBN: 3540782818
Category : Medical
Languages : en
Pages : 238
Get Book Here
Book Description
Angiogenesis is attracting increased scientific and clinical interest. The identification of novel mediators and targeting molecules has led to significant progress in our understanding of tumor angiogenesis and tumor vessel targeting. Important advances in cancer treatment have already emerged, and in the future, blood vessel targeting will play a significant role within individualized therapeutic strategies. This volume provides a general overview of the latest developments in angiogenesis inhibition in cancer. All aspects from the bench to the bedside are considered, with detailed attention both to basic research and to its translation into clinical practice. Individual chapters are devoted to the roles of angiopoietins, HIF-1a, chemokines, PDGF and VEGF, and vascular integrins. The latest results of clinical trials are presented, and various advanced targeting strategies are discussed. This book will be invaluable to all who wish to learn of the most recent advances in this exciting field.
Author: Elmer T. Skinard
Publisher: Nova Publishers
ISBN: 9781600214738
Category : Blood-vessels
Languages : en
Pages : 180
Get Book Here
Book Description
Angiogenesis -- the growth of new blood vessels -- is an important natural process occurring in the body, both for health and as related to disease. Angiogenesis occurs in the healthy body to help heal wounds and to help to restore blood flow to tissues after injury or insult. In females, Angiogenesis also occurs during the monthly reproductive cycle (to rebuild the uterus lining, to mature the egg during ovulation) and during pregnancy (to build the placenta, the circulation between mother and foetus). The healthy body controls angiogenesis through a series of "on" and "off" switches. The main "on" switches are known as angiogenesis-stimulating growth factors. The main "off switches" are known as angiogenesis inhibitors. When angiogenic growth factors are produced in excess of angiogenesis inhibitors the balance is tipped in favour of blood vessel growth. When inhibitors are present in excess of stimulators, angiogenesis is stopped. The normal, healthy body maintains a perfect balance of angiogenesis modulators. In general, angiogenesis is "turned off" by the production of more inhibitors than stimulators. Tumour angiogenesis is the proliferation of a network of blood vessels that penetrates into cancerous growths, supplying nutrients and oxygen and removing waste products. Tumour angiogenesis actually starts with cancerous tumour cells releasing molecules that send signals to surrounding normal host tissue. This signalling activates certain genes in the host tissue that, in turn, cause proteins to encourage growth of new blood vessels. This book examines its angiogenesis within the context of theory and its applications to cancer treatment.
Author: I.D. Goldberg
Publisher: Birkhäuser
ISBN: 3034890060
Category : Science
Languages : en
Pages : 437
Get Book Here
Book Description
We now know that excessive angiogenesis contributes to the development of a variety of disease processes, including cancer, chronic inflammatory disease, and diabetic retinopathy. On the other hand, insufficient angiogenesis may impair wound healing and organ repair. This volume describes recent advances in understanding the molecular regulation of angiogenesis. Subjects covered include important pro-angiogenic growth factors (e.g., vascular endothelial growth factor/vascular permeability factor, scatter factor/hepatocyte growth factor) and their receptors; angiogenesis inhibitors (e.g., thrombospondin-1, angiostatin); extracellular matrix factors (e.g., laminin) and specific vascular integrins (avb3 and avb5) that regulate angiogenesis; the roles of fibrin and the fibrinolytic system in angiogenesis; physical factors that regulate angiogenesis (hypoxia, pH); mechanisms by which specific cell types (macrophages, pericytes) regulate angiogenesis; and lymphangiogenesis, a subject often ignored in volumes of this type. Several chapters are also devoted to the prognostic and therapeutic implications of tumor angiogenesis, a subject of great interest to clinicians. Reflecting the latest advances in this exciting and expanding field, this comprehensive and authoritative monograph will prove invaluable to cell biologists, cancer researchers and pharmacologists.
Author: Atta-ur-Rahman
Publisher: Bentham Science Publishers
ISBN: 9811432864
Category : Medical
Languages : en
Pages : 212
Get Book Here
Book Description
The inhibition of angiogenesis is an effective mechanism of slowing down tumor growth and malignancies. The process of induction or pro-angiogenesis is highly desirable for the treatment of cardiovascular diseases, and wound healing disorders. Efforts to understand the molecular basis, both for inhibition and induction, have yielded fascinating results. Anti-angiogenesis Drug Discovery and Development provides an excellent compilation of well-written reviews on various aspects of the anti-angiogenesis process. These reviews have been contributed by leading practitioners in drug discovery science and highlight the major developments in this exciting field in the last two decades. The feast of these reader-friendly reviews on topics of great scientific importance – many of which are considered significant medical breakthroughs, makes this series excellent reading both for the novice as well as for expert medicinal chemists and clinicians. The fifth volume brings together reviews on the following topics: - Targeted therapy for tumor vasculature - Anti-angiogenic therapy for breast and prostate cancers (including information updates on clinical trials) - Microbe-based and other novel antiangiogenesis therapies such as chromene-based agents
Author: Atta-ur Rahman
Publisher: Elsevier
ISBN: 0128039647
Category : Science
Languages : en
Pages : 327
Get Book Here
Book Description
The inhibition of angiogenesis is an effective mechanism of slowing down tumor growth and malignancies. The process of induction or pro-angiogenesis is highly desirable for the treatment of cardiovascular diseases, wound healing disorders, and more. Efforts to understand the molecular basis, both for inhibition and induction, have yielded fascinating results. Originally published by Bentham and now distributed by Elsevier, Anti-Angiogenesis Drug Discovery and Development, Volume 2 is an compilation of well-written reviews on various aspects of the anti-angiogenesis process. These reviews have been contributed by leading practitioners in drug discovery science and highlight the major developments in this exciting field in the last two decades. These reader-friendly chapters cover topics of great scientific importance, many of which are considered significant medical breakthroughs, making this book excellent reading both for the novice as well as for expert medicinal chemists and clinicians. Edited and written by leading experts in angiogenesis drug development Reviews recent advances in the field, such as coverage of anti-angiogenetic drugs in ovarian cancer Reports current strategies and future outlook for anti-angiogenic therapy and cardiovascular diseases
Author: Atta-ur- Rahman
Publisher: Bentham Science Publishers
ISBN: 1608051625
Category : Medical
Languages : en
Pages : 197
Get Book Here
Book Description
"The inhibition of angiogenesis is an effective mechanism of slowing down tumor growth and malignancies. The process of induction or pro-angiogenesis is highly desirable for the treatment of cardiovascular diseases, wound healing disorders, etc. Efforts to"
Author: Dieter Marmé
Publisher: Springer Science & Business Media
ISBN: 3540331778
Category : Medical
Languages : en
Pages : 840
Get Book Here
Book Description
Tumor angiogenesis is one of the most prominent mechanisms driving tumor development and progression. This book is written by internationally renowned experts. Part 1 describes the basic mechanisms. Tumor-angiogenic signaling pathways are presented as new potential targets for anti-angiogenic therapy. Part 2 reviews the efforts made to validate new targets and to show efficacy in animals. Part 3 is devoted to the clinical development of the novel anti-angiogenic drugs and their use in clinical practice.
Author: Shaker A. Mousa
Publisher: CRC Press
ISBN:
Category : Medical
Languages : en
Pages : 184
Get Book Here
Book Description
The regulation of blood vessel growth underlies many normal biological processes such as reproduction, development, repair and wound healing. It also is a critical feature of pathological processes such as cancer, diabetic retinopathy, macular degeneration, inflammatory arthritis and ischemic heart disease. What causes blood vessels to grow? What inhibits their growth? This book comprehensively describes the angiogenic proteins that enhance and inhibit normal and abnormal angiogenesis. It describes the potential therapeutic applications of basic fibroblast growth factor, vascular endothelial growth factor, PECAM-1 and thrombospondin as well as other factors. The book brings together information about new blood vessel formation in many organ systems and comprises an outstanding resource on the state-of-the art in angiogenesis.
Author: Shaker Mousa
Publisher: Academic Press
ISBN: 0128026731
Category : Medical
Languages : en
Pages : 212
Get Book Here
Book Description
Anti-angiogenesis Strategies in Cancer Therapeutics provides a detailed look at the current status and future directions in the discovery and development of novel anti-angiogenesis strategies in oncology. This book highlights the different mechanisms involved in the modulation of angiogenesis, including inflammation, thrombosis, and microRNA, and shows how nanotechnology can further enhance the potential of existing and new anti-angiogenesis approaches. Written for industry scientists, researchers, oncologists, hematologists, and professors and students in the field, this comprehensive book covers all aspects of anti-angiogenesis strategies and their differences. Covers important preclinical models and clinical trials in the discovery and development of novel anti-angiogenesis agents Reviews FDA-approved anti-angiogenesis agents Illustrates the value of nanotechnology in improving the utility of anti-angiogenesis agents Offers insight into the development of novel anti-angiogenesis agents and future direction in this area
Author: Domenico Ribatti
Publisher: Springer Science & Business Media
ISBN: 1402095635
Category : Medical
Languages : en
Pages : 126
Get Book Here
Book Description
In 1971, J. Folkman published in the “New England Journal of Medicine” a hypothesis that tumor growth is angiogenesis-dependent. Folkman introduced the concept that tumors probably secrete diffusible molecules that could stimulate the growth of new blood vessels toward the tumor and that the resulting tumor neovascularization could conceivably be prevented or interrupted by angiogenesis inhibitors. Solid and haematological tumors consist of an avascular and a subsequent vascular phase. Assuming that this depends on the release of angiogenic factors, acquisition of angiogenic capability can be seen as an expression of progression from neoplastic transformation to tumor growth and metastasis. Beginning in the 1980’s, the biopharmaceutical industry began exploiting the field of antiangiogenesis for creating new therapeutic compounds for modulating new blood vessels in tumor growth. In 2004, Avastin (Bevacizumab), a humanized anti-VEGF monoclonal antibody, was the first angiogenesis inhibitor approved by the Food and Drug Administration for the treatment of colorectal cancer. At present, it has been estimated that over 20,000 cancer patients worldwide have received experimental form of antiangiogenic therapy. This book offers a historical account of the relevant literature. It also emphasizes the crucial and paradigmatic role of angiogenesis as a biological process and the significance of antiangiogenic approach for the treatment of tumors.
